Drug-Resistant Fungi Prompt a Five-Step Global Plan Ahead of WHO's 2026 Update

Why It Matters

Fungal resistance threatens vulnerable patients and fills a blind spot in current AMR policies, demanding coordinated action across health and agriculture sectors. Integrating the plan into the WHO’s 2026 update could avert a surge of untreatable infections.

Key Takeaways

• 50 researchers from 16 institutions propose five-step antifungal plan.
• Plan targets awareness, surveillance, infection control, optimized use, investment.
• Candida auris kills 1 in 3 ICU patients; Aspergillus spreads from farms.
• Agricultural fungicide use drives cross‑resistance to medical antifungals.
• Only five new antifungal classes developed in 75 years, urging prevention.

Pulse Analysis

The surge of drug‑resistant fungi is slipping under the radar of traditional antimicrobial‑resistance frameworks, which have historically prioritized bacteria and viruses. Environmental reservoirs, especially agricultural fields where azole fungicides are applied, act as breeding grounds for resistant strains that later infiltrate hospitals. This cross‑sectoral spillover underscores the necessity of a One Health perspective that aligns crop protection policies with clinical safeguards, protecting both food security and patient outcomes.

In response, a coalition of 50 scientists from 16 organizations, spearheaded by Radboudumc’s Paul Verweij, drafted a concise five‑step roadmap. The plan calls for heightened public and professional awareness, robust global surveillance networks, stringent infection‑prevention protocols, stewardship of existing antifungal agents, and dedicated funding for research and diagnostics. By feeding these recommendations into the WHO’s 2026 Global Action Plan, policymakers gain a concrete framework to set milestones, allocate resources, and monitor progress against priority fungal pathogens such as Candida auris and azole‑resistant Aspergillus fumigatus.

Developing new antifungal drugs remains a formidable challenge because fungal cells share many biological pathways with human cells, limiting therapeutic windows. Over the past three‑quarters of a century, only five novel drug classes have reached the market, leaving clinicians with a shrinking arsenal. Consequently, the emphasis must shift toward preventing resistance before it emerges. Aligning agricultural fungicide authorizations with health‑risk assessments, investing in rapid diagnostics, and accelerating pipeline research are pragmatic steps that can safeguard existing treatments and reduce mortality from invasive fungal infections. The proposed plan offers a timely, actionable blueprint to bridge the current policy gap.